HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
More on SVRA
FDA & biotech Benzinga
Savara Craters as FDA Delays Decision for Lung DiseaseSavara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.

FDA & biotech Benzinga
Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDASavara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it…
